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Background: To assess changes in survival over time of extremity soft tissue sarcoma (ESTS) patients treated at
a single reference institution.
Patients and methods: Patients with primary localized adult-type ESTS surgically treated at our institution between
1987 and 2007 were retrospectively reviewed. Patients were categorized into four 5-year groups according to the
timing of their first operation. Crude cumulative incidence (CCI) of sarcoma-specific mortality (SSM), local recurrence
(LR), and distant metastases (DMs) were calculated for each time period.
Results: A total of 1094 patients were identified. Median follow-up was 81 months. CCI of SSM and LR were
significantly better in period 4 in comparison to periods 1–3 (P < 0.001 for both end points), dropping, respectively,
from 15% to 6% and from 23% to 9%. An overall improvement of DMs-free survival at 5 years could be detected in the
latter period, as well as a better postmetastasis survival.
Conclusions: Reference institutions for sarcomas may have improved their outcome in the last years. Although
biases of retrospective analyses as well as the effect of institutional learning curves need to be discounted, it is
possible that optimal exploitation of a series of subtle improvements in sarcoma treatment may make a difference in
results currently achievable.
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introduction
Extremity soft tissue sarcomas (ESTS) are a heterogenous
group of rare diseases, whose prognosis has been extensively
studied over the past years. The availability of large
institutional prospective databases has helped to identify
clinical predictors of outcome, related to either the tumor
biology (size, histological grade of aggressiveness, histolgical
subtype, and depth) or the treatment (surgical margins,
delivery of radiotherapy, and chemotherapy) [1–6]. The
notion that tumor biology prevails over the extent of local
treatment as the primary determinant of patient outcome has
led to the acceptance of limb- and function-sparing procedures
[7–10]. If the appropriateness of local treatment was first
viewed as determined by radical surgery alone, it is now seen as
the product of surgical resection and complementary
treatments. A multimodal approach, including radiation
therapy and chemotherapy, has been increasingly used in the
management of high-risk ESTS in the last years [11, 12]. In
addition to a better understanding of prognostic factors and an
evolution in the clinical management of patients with STS,
insights from molecular studies promise to allow an even
better risk stratification in the future, at a time when
molecular-targeted agents are entering the armamentarium of
sarcoma medical oncologists, and even chemotherapy is
refined, through its tailoring to the histological variety of STS
[12–14].
In light of all this, we decided to retrospectively evaluate
whether there have been any major change in survival over
time of ESTS patients treated at our institute in a 20-year time
span.
patients and methods
Between January 1987 and December 2007, 1094 consecutive adult patients
affected by primary adult-type ESTSs were operated on with a curative
intent at the Istituto Nazionale Tumori, Milan, Italy, within a dedicated
surgical unit. Clinical data were extracted from a prospective database of all
adult patients with soft tissue sarcoma. Well-differentiated liposarcoma,
dermatofibrosarcoma protuberans, and desmoid-type fibromatosis
were excluded from the present analysis, since they virtually never
metastasize.
For the purpose of the present analysis, patients were grouped according
to the calendar time of first operation at our Institution, taking into
account the following periods: 1987–1992, 1993–1997, 1998–2002, and
2003–2007.
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Data retrieved included gender, age at diagnosis, site, size, depth,
histotype, grade and margin status, adjuvant treatments, dates of neoplastic
events, death, or last follow-up.
Tumors were characterized as superficial or deep according to the
involvement of the investing fascia. Pathologically, all tumors were
diagnosed by two experienced pathologists at our institution. The
Fe´de´ration Nationale des Centers de Lutte Contre le Cancer (FNCLCC)
[15] grading system was applied to the untreated primary tumors.
Surgical excisions were considered as macroscopically complete in the
absence of gross residual disease. The surgical specimen was examined in
the presence of the operating surgeon; margins were inked and separately
sampled. All macroscopically complete resections were classified according
to the closest surgical margin, which was microscopically categorized as
positive (tumor within 1 mm from the inked surface, R1) or negative
(absence of tumor within 1 mm from the inked surface, R0).
The indication to radiation therapy (RT) was given by both the operating
surgeon and the radiation oncologist when a higher risk of relapse was
supposed to exist on clinical grounds. However, no prospectively selected
criteria were used to this end. External beam radiation was used in all such
cases, and doses ranged from 45 to 70 Gy (median 60 Gy).
Chemotherapy (CT) was given at the discretion of the multidisciplinary
institutional sarcoma board or as part of ongoing clinical trials.
Anthracycline-based regimens were used, in most of the cases combined
with ifosfamide.
In the absence of any event after treatment, all patients were regularly
followed up, generally at least every 4 months for the first 2 years, then
every 6 months for the following 3 years, and then yearly.
statistical methods
The prognostic analyses mainly focused on investigating the prognostic
effect of first calendar time on the following end points: sarcoma-specific
mortality (SSM), local recurrence (LR), and distant metastases (DMs).
Concomitant local relapses and DMs were included in the computations as
DMs. The analyses were carried out in a competing risks framework [16]; in
the analysis of cause-specific mortality, deaths due to conditions unrelated
with sarcoma were regarded as competing events. For LR and DMs analyses,
deaths without evidence of disease and DMs, or LR, respectively, whichever
occurred first, were regarded as competing events. Time to events was
computed from the date of surgery at our institution, or censored at the
date of last follow-up assessment for event-free subjects.
Crude cumulative incidence (CCI) curves were estimated in the four time
periods and compared by means of the Gray test [17].
Multivariable analyses of the effect of calendar time were based on cause-
specific hazards and were therefore carried out using Cox regression
models. The following covariates, chosen on the ground of literature
information and our past experience [1, 4, 6, 18], were included in the
models for the purpose of adjustment: patient age, tumor size, depth,
grading, histotype, surgical margins, pre- and postoperative chemotherapy,
and radiotherapy. The models also included interaction terms suitable to
take into account possible synergism between preoperative CT and RT [19]
and the temporal trends in the adoption of their combination. Patient age
and tumor size were modeled as continuous variables by using four-knot
restricted cubic splines [20] to obtain flexible fits, by allowing their
prognostic effect not to be the same in every part of the range, whereas the
other covariates were modeled as categorical by using dummy variables.
An additional analysis was carried out by including (first) local relapse
and DMs as time-dependent variables in the multivariable Cox model
on SSM, so as to verify their relative impact on sarcoma mortality.
Additional descriptive analyses of times to events were based on Kaplan–
Meier method for the estimation of survival curves.
We considered as significant two-sided P values below the 5%
conventional threshold.
All statistical analyses were carried out using the SAS (SAS Institute Inc.,
Cary, NC) and the R software [R Development Core Team. R: A Language
and Environment for Statistical Computing. R Foundation for Statistical
Computing, Vienna, Austria, 2006; http://www.r-project.org/
(24 November 2009, date last accessed)].
results
Main patient characteristics are listed in Table 1.
Median follow-up (interquartile range) was 81 months (40–
121 months) in the whole series [127 (106–168), 123 (114–
141), 95 (77–115), and 38 (26–54) in the first to fourth period,
respectively].
disease-specific mortality
Out of 1094 patients investigated, 247 deaths were recorded.
Of these, 199 (81%) were related to ESTS and were
thus considered in our analyses. The number of deaths
related to STS and the 5- and 10-year crude
cumulative mortality estimates according to period are
reported in Table 2.
Crude cumulative mortality curves (Figure 1, panel
A) differed significantly according to period (P = 0.001).
The cause of death was mainly related to DMs in all four
periods; nine patients overall (four in the first period, one in
the second, three in the third, and one in the fourth) died of
exclusive locoregional disease without having developed any
DMs.
Table 3 shows the results from the multivariable Cox
regression model for the whole case series. Significant
prognostic factors were size, histological grade, histological
subtype, surgical margins, and neoadjuvant CT-RT interaction,
along with the period.
The period of the first treatment was no longer significant
when including LR and DMs as additional (time-dependent)
variables into the Cox model (P = 0.136).
local recurrence
One-hundred and sixty-five patients developed LR (Table 2).
Overall, 76 patients had only LR, while 89 had LR and DMs (LR
anticipating DMs in 49 patients, being concurrent in 23 and
posterior in 17). In the first, second, third, and fourth period,
respectively, 26, 21, 17, and 12 patients had a LR alone, while
30, 25, 22, and 12 had a LR and DMs (LR anticipating DMs in
15, 17, 11, and 6 patients, being concurrent in 8, 8, 5, and 6 and
posterior in 7, 4, 6, and 0 patients).
One-hundred and twenty-five recurrences occurred as first
event; the 5- and 10-year CCI estimates according to period are
reported in Table 2. CCI curves (Figure 1, panel B) differed
significantly according to period (P < 0.001).
Table 3 shows the results from the multivariable Cox
regression model. Significant prognostic factors were age and
surgical margins along with the period of the first treatment.
distant metastases
Two-hundred and ninety-six patients developed DMs
(Table 2). Overall, 207 patients had only DMs, while 89 had
a LR and DMs, as reported above. In the first, second, third,
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and fourth period, respectively 52, 33, 58, and 64 patients had
only DMs, while 30, 25, 22, and 12 had a LR and DMs, as
reported above.
The 5- and 10-year CCI estimates according to period are
reported in Table 2. CCI curves (Figure 1, panel C) were not
significantly different according to period (P = 0.266).
Table 1. Main patients and disease characteristics according to the calendar time of operation
1987–1992 1993–1997 1998–2002 2003–2007 Overall
N 250 194 274 376 1094
Median age, years (IQ) 47 (32–59) 49 (34–61) 54 (36–66) 51 (37–65) 50 (36–64)
Gender
Female 117 (46.8%) 102 (52.6%) 122 (44.5%) 175 (46.5%) 516 (47.2%)
Male 133 (53.2%) 92 (47.4%) 152 (55.5%) 201 (53.5%) 578 (52.8%)
Median tumor size, cm (IQ) 7 (3.3–12) 6 (4–10) 6 (3–10) 6 (3–10) 6 (3–10)
Tumor site
Upper extremity 46 (18.4%) 37 (19.1%) 60 (21.9%) 79 (21.0%) 222 (20.3%)
Lower extremity 189 (75.6%) 142 (73.2%) 185 (67.5%) 270 (71.8%) 786 (71.8%)
Girdle 15 (6.0%) 15 (7.7%) 29 (10.6%) 27 (7.2%) 86 (7.9%)
Depth
Superficial 22 (8.8%) 16 (8.3%) 88 (32.1%) 138 (36.7%) 264 (24.1%)
Deep 228 (91.2%) 178 (91.7%) 186 (67.9%) 238 (63.3%) 830 (75.9%)
Grade
GI 39 (15.6%) 49 (25.3%) 75 (27.4%) 87 (23.2%) 250 (22.9%)
GII 44 (17.6%) 59 (30.4%) 96 (35.0%) 102 (27.1%) 301 (27.5%)
GIII 167 (66.8%) 86 (44.3%) 103 (37.6%) 187 (49.7%) 543 (49.6%)
Histological subtype
Myxoid/round cell
liposarcoma
38 (15.2%) 42 (21.5%) 42 (15.3%) 52 (13.8%) 174 (15.9%)
Dedifferentiated
liposarcoma
16 (6.4%) 10 (5.2%) 12 (4.4%) 17 (4.5%) 55 (5.0%)
Synovial sarcoma 37 (14.8%) 29 (15.0%) 27 (9.9%) 35 (9.3%) 128 (11.7%)
Leiomiosarcoma 31 (12.4%) 24 (12.3%) 53 (19.3%) 79 (21.0%) 187 (17.1%)
MPNST 22 (8.8%) 15 (7.7%) 20 (7.3%) 29 (7.7%) 86 (7.9%)
MFH 59 (23.6%) 38 (19.6%) 61 (22.3%) 82 (21.8%) 240 (21.9%)
Vascular sarcoma 7 (2.8%) 3 (1.6%) 9 (3.3%) 3 (0.8%) 22 (2.0%)
Other 40 (16.0%) 33 (17.1%) 50 (18.2%) 79 (21.0%) 202 (18.5%)
Surgical procedure
Conservative 229 (91.6%) 190 (97.9%) 271 (98.9%) 373 (99.2%) 1063 (97.2%)
Amputation 21 (8.4%) 4 (2.1%) 3 (1.1%) 3 (0.8%) 31 (2.8%)
Reconstructive procedures
Yes 24 (9.6%) 12 (6.2%) 37 (13.5%) 76 (20.2%) 149 (13.6%)
No 226 (90.4%) 182 (93.8%) 237 (86.5%) 300 (79.8%) 945 (86.4%)
Surgical margins
R0 215 (86.0%) 164 (84.5%) 250 (91.2%) 333 (88.6%) 962 (87.9%)
R1 35 (14.0%) 30 (15.5%) 24 (8.8%) 43 (11.4%) 132 (12.1%)
CT
Not carried out 200 (80.0%) 166 (85.6%) 219 (79.9%) 259 (68.8%) 844 (77.1%)
Preoperative/pre- and
postoperative
44 (17.6%) 14 (7.2%) 25 (9.1%) 87 (23.1%) 170 (15.5%)
Combined with RT 1 (0.4%) 0 (0%) 6 (2.2%) 45 (12.0%) 52 (4.8%)
Postoperative 6 (2.4%) 14 (7.2%) 30 (11.0%) 30 (8.0%) 80 (7.3%)
Combined with RT 3 (1.2%) 12 (6.2%) 26 (9.5%) 28 (7.5%) 69 (6.3%)
RT
Not carried out 169 (67.6%) 123 (63.4%) 134 (48.9%) 150 (40.0%) 576 (52.7%)
Preoperative/pre- and
postoperative
2 (0.8%) 0 (0%) 9 (3.3%) 47 (12.5%) 58 (5.3%)
Combined with CT 1 (0.4%) 0 (0%) 6 (2.2%) 45 (12.0%) 52 (4.8%)
Postoperative 79 (31.6%) 71 (36.6%) 131 (47.8%) 179 (47.6%) 460 (42.0%)
Combined with CT 3 (1.2%) 12 (6.2%) 26 (9.5%) 28 (7.5%) 69 (6.3%)
IQ, interquartile range; MPNST, malignant peripheral nerve sheath tumor; MFH, malignant fibrous histiocytoma.
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Table 3 shows the results from the Cox multiple regression
model. Significant prognostic factors were size, histological
grade, and histological subtype, but not period of the first
treatment.
DMs-free survival, taking into account all DMs (either
occurred as first event or not), showed a significant better
outcome in the fourth period in comparison with all the three
previous ones (Figure 2; P = 0.020).
The median time from metastases to death was 17 months in
the first three periods of time and approached 31 months in the
last one (Figure 3).
The above findings were confirmed also on both the high-
grade and the deep-tumor subgroups (data not shown).
discussion
Over a period of 20 years, in a single-institution series of
patients with primary localized ESTS, the 5-year LR and cause-
specific death incidence dropped from 15% and 23%,
respectively, to 6% and 9%. Both improvements were
statistically significant and hold true even in the subgroups of
grade III and deep tumors.
All retrospective analyses have obvious weaknesses. A Will
Rogers phenomenon [21] could be advocated to explain the
improved outcome. Nevertheless if that was real, we would
expect to observe an overall improvement even in the CCI of
DMs, which did not occur. On the other hand, an absolute
improvement in the 10% range in both LR and survival is
worthy of notice. No known breakthrough in ESTS treatment
has occurred in the same time interval as to justify such
a difference. Institutional learning curves do exist, of course,
and may improve outcomes over time. If so, it would be
noteworthy as well, implying that room for improvement does
exist for sarcoma institutions at the best of current knowledge.
Indeed, there was a higher resort to reconstructive surgery in
the last period (from <10% of the cases in the first periods
to >20% in the last one). This was accompanied by a decrease
in amputations (which dropped to 0.8%), and may have thus
resulted in more aggressive, albeit conservative, surgery.
Another major difference in treatment among the four time
Table 2. Number of events according to calendar time of operation and corresponding incidence estimates
No. of events 5-Year estimates 10-Year estimates
No. of patients Overall First event CCI CI CCI CI
1987–1992 250
SSM 67 – 23.0% 18.1, 29.2% 29.5% 24.0, 36.2%
LR 56 41 15.1% 11.2, 20.4% 17.5% 13.2, 23.1%
DM 82 67 26.8% 21.7, 33.1% 28.2% 23.0, 34.5%
1993–1997 194
SSM 46 – 19.8% 14.8, 26.5% 23.2% 17.8, 30.2%
LR 46 38 18.3% 13.5, 24.7% 19.4% 14.5, 26.0%
DM 58 41 18.4% 13.6, 24.8% 21.9% 16.7, 28.8%
1998–2002 274
SSM 59 – 19.4% 15.2, 24.9% 23.0% 18.3, 29.0%
LR 39 28 9.8% 6.8, 14.1% 11.0% 7.7, 15.6%
DM 80 69 24.3% 20.0, 30.1% 26.2% 21.3, 32.1%
2003–2007a 376
SSM 27 – 9.2% 6.2, 13.7% – –
LR 24 18 6.0% 3.6, 9.8% – –
DM 76 70 22.2% 17.5, 28.2% – –
aDue to the short follow-up in this subgroup, the CCI was not extrapolated to 10 years.
CCI, crude cumulative incidence; CI, CCI 95% confidence interval; LR, local recurrence; DMs, distant metastases; SSM, sarcoma-specific mortality.
Figure 1. Crude cumulative incidence of sarcoma-specific mortality (panel A), local recurrence (panel B), and distant metastases (panel C) by calendar time
of operation.
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cohorts was the introduction at our institution of preoperative
combined chemoradiation therapy in the latter period
(practically never employed in the first three periods, while
used in 12% of the cases in the last one). The choice to do
a preoperative combined treatment was not randomized, even
when it was made within a clinical study, and was mainly based
Table 3. Analysis of the effect of calendar time of operation on SSM, LR, and DM by multivariable Cox models
SSM LR DMs
Factor HR CI P HR CI P HR CI P
Calendar time 0.005 0.006 0.278
1987–1992 versus
2003–2007
1.67 0.98, 2.83 2.68 1.42, 5.02 1.25 0.84, 1.86
1993–1997 versus
2003–2007
2.00 1.17, 3.43 2.79 1.50, 5.17 1.12 0.73, 1.72
1998–2002 versus
2003–2007
2.38 1.46, 3.89 1.71 0.93, 3.14 1.41 0.99, 2.01
Age, years
64 versus 36a 1.13 0.86, 1.48 0.678 1.80 1.26, 2.56 0.005 1.01 0.80, 1.29 0.880
Tumor size, cm
10 versus 3a 2.62 1.75, 3.92 <0.001 1.35 0.85, 2.15 0.248 3.23 2.20, 4.75 <0.001
Depth
Deep versus superficial 1.86 1.00, 3.45 0.051 1.28 0.72, 2.27 0.401 1.02 0.65, 1.61 0.928
Grading <0.001 0.209 <0.001
II versus I 3.53 1.73, 7.18 1.61 0.89, 2.91 2.98 1.68, 5.29
III versus I 6.29 3.11, 12.71 1.22 0.66, 2.27 5.08 2.87, 8.98
Histotype <0.001 0.102 <0.001
Myxoid/round cell
liposarcoma versus
MFH
1.50 0.76, 2.96 0.54 0.27, 1.06 1.44 0.82, 2.52
Dedifferentiated
liposarcoma versus
MFH
1.90 0.94, 3.85 0.60 0.27, 1.35 1.61 0.86, 3.01
Synovial sarcoma versus
MFH
3.90 2.23, 6.82 1.01 0.54, 1.88 2.86 (1.73, 4.73)
Leiomiosarcoma versus
MFH
2.93 1.73, 4.97 0.54 0.30, 0.99 3.06 1.98, 4.72
MPNST versus MFH 2.63 1.43, 4.84 0.77 0.39, 1.53 1.58 0.86, 2.93
Vascular sarcoma
versus MFH
6.49 2.72, 15.49 1.30 0.45, 3.74 3.98 1.65, 9.64
Other versus MFH 2.06 1.18, 3.59 0.45 0.24, 0.87 2.18 1.38, 3.46
Surgical margins
R1 versus R0 1.49 1.02, 2.16 0.037 2.52 1.62, 3.90 <0.001 1.17 0.82, 1.69 0.385
Interaction preoperative
CT–RT
0.015 0.334 0.055
Preoperative CT 0.048 0.511 0.150
Yes versus no, without
preoperative RT
1.19 0.80, 1.78 0.86 0.43, 1.69 1.15 0.80, 1.66
Yes versus no, with
preoperative RT
0.24 0.07, 0.84 0.21 0.01, 3.50 0.36 0.11, 1.14
Preoperative RT 0.027 0.334 0.028
Yes versus no without
preoperative CT
4.00 1.40, 11.43 1.12 0.15, 8.61 4.06 1.42, 11.60
Yes versus no, with
preoperative CT
0.79 0.34, 1.83 0.27 0.03, 2.20 1.28 0.68, 2.39
Postoperative CT
Yes versus no 0.91 0.61, 1.36 0.642 1.60 0.87, 2.94 0.134 0.80 0.56, 1.14 0.208
Postoperative RT
Yes versus no 0.90 0.65, 1.24 0.523 0.73 0.48, 1.09 0.123 1.26 0.93, 1.70 0.134
aModeled as continuous variable (see ‘Statistical methods’ section); the two values are third and first quartiles, respectively.
HR, hazard ratio; CI, HR 95% confidence interval; P, two-sided Wald test P value; LR, local recurrence; DMs, distant metastases; SSM, sarcoma-specific mortality;
MPNST, Malignant Peripheral Sheath Tumor; MFH, Malignant Fibrous Histiocytoma.
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on the clinical perception of a higher risk or tumor volume. We
do not have data formally proving the added value of
preoperative radiation therapy [19]. Indeed, the role of
radiation therapy as such in complementing surgery was
proved by small, though convincing, randomized trials more
than a decade ago [8, 9]. Whether doing radiation therapy pre-
or postoperatively makes a difference in terms of local outcome
has been addressed in part by a randomized trial [22]. The
study focused on differences in complications but was not
powered enough to say if the local control was affected by the
pre- versus postoperative placement of radiation therapy. Yet
several groups have started to employ radiation therapy in the
preoperative setting, reporting lower local failures [19, 23, 24]
in comparison to previous historical series [4, 18, 25, 26]. These
studies are small and not conclusive. On the other hand, the
role of adjuvant chemotherapy in STS has been debated for
years without any definitive conclusion [27, 28]. A recent meta-
analysis [29] of all published studies suggested a minor
improvement in outcome, both through a local and a distant
effect. All the more, whether its placement preoperatively
makes a difference is unknown (even in osteosarcoma, where
a much more effective CT is available, a randomized trial did
not show any difference between pre- and postoperative
chemotherapy [30]). In the end, it is possible that exploiting at
best reconstructive surgery and preoperative combined
radiochemotherapy may make a difference in some patients. At
least, our institutional improvement in local control suggests to
assess this hypothesis.
In addition to a better local control, we saw an improvement
in cause-specific mortality, in the lack of any improvement in
the incidence of DMs as the first failing event. In principle, the
most logical explanation would be that a better local control
gives also a survival improvement. As well-known, no definitive
formal demonstration of this is available at the moment,
although this has been the subject of continuous controversy in
the sarcoma community. Some believe that LR is just a marker
of tumor aggressiveness [18, 25, 31]. Others believe that,
though minor, a causative effect on distant spread might be in
place [10, 23]. Far from saying a final word on this, in the last
period we observed an absolute reduction in DMs (from 34%
to 27% at 5 years, Figure 2), in the face of the same rate of DMs
as a first event in the four periods. In practice, we cannot rule
out that the absence of LRs in a number of patients may have
prevented them from developing metastases thereby.
At least, in this series we saw that a small fraction of patients
experiencing a LR die because of it, without developing any
distant failure, as we already reported [32]. In this series, these
patients represent 20% of those having LRs. It is therefore quite
reasonable to think that, by reducing the LR rate, some patients
were cured, who would have developed a LR and died from it.
However, this may account for only 1%–2% improvement in
5-year mortality (the 3% rate of patients who died in the first
three periods for locoregional recurrences without metastatic
spread dropped to 1.2% in the last period).
Finally, we observed a longer postmetastasis survival, which
definitely may have contributed to an overall survival
improvement at 5 years (although this improvement,
obviously, will not hold at a longer interval). In fact, median
survival of metastatic patients in the previous years was 17
months, while it was 31 months in the last period. This
improvement might reflect a more individualized approach to
the medical therapy of metastatic disease in the most recent
years. Indeed, new agents, tailored to the histological subtype,
have been entering our everyday practice in the last years [14].
As well-known, even the superiority of multiagent
chemotherapy over single-agent doxorubicin in first line has
long been debated in STS. However, the availability of
histology-driven salvage therapies has recently added to the
armamentarium of the medical oncologist [33–36]. In a patient
setting marked by preserved performance status across the
advanced stages of disease, their use may result in some survival
prolongation. Likely, it will be difficult to prove this in
subgroups of patients, within a rare group of diseases like
sarcomas. Thus, signals like this institutional improvement in
the 5-year postmetastasis survival may be of interest to the
sarcoma community.
In conclusion, sarcoma institutions should know that there is
room for improving their local control rate and possibly their
final outcome. Reconstructive surgery and possibly
preoperative therapies may have a crucial added value. Even
Figure 2. Distant metastases-free survival by period of primary treatment.
Figure 3. Postmetastases survival by period of primary treatment.
original article Annals of Oncology
1680 | Gronchi et al. Volume 22 | No. 7 | July 2011
D
ow
nloaded from
 https://academ
ic.oup.com
/annonc/article-abstract/22/7/1675/187506 by U
niversità degli Studi di M
ilano user on 17 M
ay 2019
postmetastasis survival might be currently improving, possibly
thanks to a refined, histology-driven approach to the medical
therapy of advanced sarcomas. At least, these are suggestions
drawn from the retrospective analysis of a single-institution
series. Other institutions may be willing to look at their data in
order to confirm this, while hypotheses suggested from these
data may drive prospective studies, challenging though they
may be in a rare family of 50-plus histological subgroups of
tumors.
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